Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not recruiting

Study on the Effects of Povorcitinib for Patients with Prurigo Nodularis

Verified siteInvestigational
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying the effects of a medication called Povorcitinib on a skin condition known as Prurigo Nodularis. Prurigo Nodularis is a chronic skin disease characterized by itchy nodules or bumps on the skin. The purpose of the study is to evaluate how well Povorcitinib can reduce itchiness and improve skin lesions in individuals with this condition.

Participants in the study will be randomly assigned to receive either Povorcitinib or a placebo, which is a substance with no active medication. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo. This helps ensure that the results are unbiased. The treatment will be administered in the form of tablets taken orally, and the study will last for a period of up to 48 weeks.

Throughout the study, participants will be monitored to assess the effectiveness and safety of Povorcitinib. The main goal is to see if there is a significant improvement in the itchiness and appearance of the skin lesions by the end of the study period. Participants will have regular check-ups to track their progress and any changes in their condition.

The research process

The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Joining the study

    Upon joining the study, you will be randomly assigned to receive either the medication povorcitinib or a placebo. A placebo is a substance with no active medication, used to compare the effects of the actual drug.

  2. Step 2

    Medication administration

    You will take the assigned medication in the form of a tablet by mouth. The exact dosage and frequency will be provided by the study team. It is important to follow the instructions carefully for the duration of the study.

  3. Step 3

    Regular check-ups

    Throughout the study, you will have regular check-ups to monitor your health and the effects of the medication. These check-ups will include assessments of your itch and skin condition.

  4. Step 4

    Evaluation of progress

    At week 24, your progress will be evaluated to determine the effectiveness of the treatment. This will involve measuring improvements in itch and skin lesions.

  5. Step 5

    Completion of the study

    Once the study is completed, you will receive information about the results and any next steps. Your participation will contribute to understanding the treatment of prurigo nodularis.

Who can join the trial?

9 criteria

  • Ability to understand and willingness to sign a written consent form for the study.
  • Age between 18 and 75 years.
  • Clinical diagnosis of Prurigo Nodularis (PN) for at least 3 months before the start of the study.
  • Pruritus, which means itching, with an average itch score of 7 or higher during the 7 days before the study starts.
  • At least 20 itchy skin bumps in total on at least 2 different body areas (such as both legs, both arms, or the trunk) at the start of the study.
  • IGA-CPG-S score of 3 or higher at the start of the study. This is a score used to measure the severity of skin conditions.
  • History of treatment failure, intolerance, or inability to use a previous treatment for PN, except for certain types of treatments called JAK or TYK2 inhibitors.
  • Willingness to avoid pregnancy or fathering children during the study, following specific guidelines.
  • Willing and able to follow the study rules and procedures.

Who cannot join the trial?

9 criteria

  • Participants with any other skin condition that might interfere with the study results.
  • Participants who have had a recent infection that required treatment with antibiotics, antivirals, or antifungals.
  • Participants who have a history of cancer, except for certain types of skin cancer that have been treated.
  • Participants who have a history of severe allergic reactions.
  • Participants who are currently using other medications that might interfere with the study treatment.
  • Participants who have a history of drug or alcohol abuse within the past year.
  • Participants who are pregnant or breastfeeding.
  • Participants who have participated in another clinical trial within the last 30 days.
  • Participants with any other medical condition that the study doctors think might make it unsafe for them to participate.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

Povorcitinib is a medication being studied for its potential to help people with a skin condition called prurigo nodularis. This condition causes very itchy bumps on the skin. Povorcitinib is being tested to see if it can reduce the itchiness and improve the appearance of the skin lesions. The trial aims to determine how effective and safe this medication is for people suffering from this condition.

What is already known about the treatment

Povorcitinib – Povorcitinib is administered orally in the form of a tablet. It is currently being studied in a Phase 3 clinical trial to assess its effectiveness and safety for treating Prurigo Nodularis, a skin condition characterized by itchy nodules. The main goal of the trial is to see how well povorcitinib can reduce itchiness and improve skin lesions in affected individuals. At the molecular level, povorcitinib works by inhibiting certain enzymes that play a role in the inflammatory process, which helps to alleviate symptoms. It is classified pharmacologically as a Janus kinase (JAK) inhibitor.

Investigated diseases

Prurigo Nodularis – Prurigo Nodularis is a chronic skin condition characterized by the presence of hard, itchy nodules on the skin. These nodules are often intensely itchy, leading to frequent scratching, which can worsen the condition. The nodules typically appear on the arms, legs, and other areas that are easy to reach. Over time, the skin around the nodules may become thickened and discolored due to repeated scratching and inflammation. The exact cause of Prurigo Nodularis is not well understood, but it is believed to be related to an overactive immune response. The condition can persist for many years, with periods of improvement and worsening.
Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase IIITrial ID2024-511881-35-00Protocol codeINCB 54707-306Estimated enrolment359 patientsSponsorIncyte Corp.

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.